Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Quercetin (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAT IQ
- 22 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Jan 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2022.
- 31 Aug 2018 Biomarkers information updated